RU2002113759A - Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII - Google Patents

Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII

Info

Publication number
RU2002113759A
RU2002113759A RU2002113759/04A RU2002113759A RU2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759/04 A RU2002113759/04 A RU 2002113759/04A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A
Authority
RU
Russia
Prior art keywords
formula
compounds
diseases
imidazole
solvates
Prior art date
Application number
RU2002113759/04A
Other languages
English (en)
Inventor
Ханс Михаэль ЭГГЕНВАЙЛЕР (DE)
Ханс Михаэль ЭГГЕНВАЙЛЕР
Рохус ЙОНАС (DE)
Рохус ЙОНАС
Михаэль ВОЛЬФ (DE)
Михаэль Вольф
Михаель ГАССЕН (DE)
Михаель ГАССЕН
Томас ВЕЛЬГЕ (DE)
Томас ВЕЛЬГЕ
Original Assignee
Мерк Патент ГмбХ (DE)
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент ГмбХ (DE), Мерк Патент Гмбх filed Critical Мерк Патент ГмбХ (DE)
Publication of RU2002113759A publication Critical patent/RU2002113759A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)

Claims (7)

1. Соединения имидазола формулы
Figure 00000001
в которых R1 и R2, независимо друг от друга, обозначают А1, ОА1, SA1
или Hal;
А1 обозначает Н, А, алкенил, циклоалкил или алкиленциклоалкил;
А обозначает алкил, содержащий 1-10 атомов углерода;
Hal обозначает F, CI, Вг или I;
Х обозначает О, S, SO или SO2,
и их физиологически приемлемые соли и/или сольваты.
2. Соединения имидазола формулы I по п.1 и их физиологически приемлемые соли и сольваты в качестве медицинских препаратов.
3. Медицинские препараты по п.2 для ингибирования фосфодиэстеразы VII.
4. Медицинские препараты по п.3 для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
5. Фармацевтические препараты, содержащие, по крайней мере, один медицинский препарат по одному из пп.3 и 4, которые могут содержать также эксципиенты и/или вспомогательные вещества и другие активные ингредиенты.
6. Применение соединений формулы I по п.1 и/или их физиологически приемлемых солей или сольватов в приготовлении медицинских препаратов для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
7. Способ получения соединений формулы I по п.1 и их солей, отличающийся тем, что проводят реакцию соединений формулы II
Figure 00000002
в которой R1, R2 и Х соответствуют приведенным выше определениям;
L обозначает Cl, Br, ОН, SCH3 или активную этерифицированную группу ОН, с имидазолом,
и/или соединение формулы I преобразуют в одну из его солей.
RU2002113759/04A 1999-11-13 2000-10-31 Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII RU2002113759A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954707A DE19954707A1 (de) 1999-11-13 1999-11-13 Imidazolverbindungen als Phosphodiesterase VII-Hemmer
DE19954707.6 1999-11-13

Publications (1)

Publication Number Publication Date
RU2002113759A true RU2002113759A (ru) 2004-01-10

Family

ID=7928973

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002113759/04A RU2002113759A (ru) 1999-11-13 2000-10-31 Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII

Country Status (23)

Country Link
US (1) US6884800B1 (ru)
EP (1) EP1228073B1 (ru)
JP (1) JP4819272B2 (ru)
KR (1) KR20020049051A (ru)
CN (1) CN1390222A (ru)
AR (1) AR026421A1 (ru)
AT (1) ATE245653T1 (ru)
AU (1) AU775886B2 (ru)
BR (1) BR0015487A (ru)
CA (1) CA2391087A1 (ru)
CZ (1) CZ20021474A3 (ru)
DE (2) DE19954707A1 (ru)
DK (1) DK1228073T3 (ru)
ES (1) ES2200968T3 (ru)
HU (1) HUP0203422A3 (ru)
MX (1) MXPA02004728A (ru)
NO (1) NO20022232L (ru)
PL (1) PL355098A1 (ru)
PT (1) PT1228073E (ru)
RU (1) RU2002113759A (ru)
SK (1) SK6012002A3 (ru)
WO (1) WO2001036425A2 (ru)
ZA (1) ZA200204729B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (en) * 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR102640696B1 (ko) 2017-07-12 2024-02-27 다트 뉴로사이언스, 엘엘씨 Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919271A (en) 1957-12-05 1959-12-29 Smith Kline French Lab 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity

Also Published As

Publication number Publication date
US6884800B1 (en) 2005-04-26
HUP0203422A2 (hu) 2003-02-28
PT1228073E (pt) 2003-12-31
WO2001036425A2 (de) 2001-05-25
JP4819272B2 (ja) 2011-11-24
EP1228073B1 (de) 2003-07-23
AU775886B2 (en) 2004-08-19
CA2391087A1 (en) 2001-05-25
DE50003036D1 (de) 2003-08-28
DK1228073T3 (da) 2003-11-03
CN1390222A (zh) 2003-01-08
NO20022232D0 (no) 2002-05-10
PL355098A1 (en) 2004-04-05
EP1228073A2 (de) 2002-08-07
JP2003514821A (ja) 2003-04-22
ATE245653T1 (de) 2003-08-15
SK6012002A3 (en) 2002-09-10
BR0015487A (pt) 2002-07-02
ES2200968T3 (es) 2004-03-16
MXPA02004728A (es) 2002-08-30
CZ20021474A3 (cs) 2002-07-17
HUP0203422A3 (en) 2004-12-28
KR20020049051A (ko) 2002-06-24
WO2001036425A3 (de) 2002-01-10
AR026421A1 (es) 2003-02-12
ZA200204729B (en) 2003-11-26
DE19954707A1 (de) 2001-05-17
NO20022232L (no) 2002-05-10
AU1390701A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
RU2002113759A (ru) Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII
RU2002113750A (ru) Производные пиррола в качестве ингибиторов фосфодиэстеразы VII
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
EP1439837B1 (en) Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
AU2018306619A1 (en) Immunomodulator compounds
AR016133A1 (es) Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
GB9900334D0 (en) Tricylic vascular damaging agents
CA2160928A1 (en) Compounds as pde iv and tnf inhibitors
WO1998052549B1 (de) Verwendung von fumarsäurederivaten
CN104837825A (zh) 鲁顿酪氨酸激酶抑制剂
RU2000132188A (ru) Производные эпотилонов, их синтез и применение
AR014903A1 (es) Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria
SK281318B6 (sk) Amidy kyseliny hydroxyalkylidénkyanoctovej, farmaceutický prostriedok obsahujúci tieto zlúčeniny a ich použitie
EP1438295A2 (en) Azole derivatives and pharmaceutical compositions containing them
KR890013035A (ko) 인돌로카르바졸 유도체와 그 제조방법 및 그들을 함유하는 약제조성물
RU99105211A (ru) Арилалканоилпиридазины
RU99127433A (ru) Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина
JPH01246281A (ja) 向精神性作用化合物及びその調製法
CN101341150A (zh) 硝基咪唑化合物
RU2002113746A (ru) Производные изоксазола в качестве ингибиторов фосфодиэстеразы VII
JP3122161B2 (ja) γ−ラクトン免疫抑制剤
RU2222541C2 (ru) Оптически активные производные пирролопиридазина, способы их получения, фармацевтическая композиция и агент на их основе, способ лечения или профилактики язвенной болезни
RU2002105518A (ru) Гетероциклические соединения, ингибирующие ангиогенез
RU2222537C2 (ru) Новые производные морфолина, способ их получения и содержащие их фармацевтические композиции
CN1070909A (zh) 硫脲衍生物和含该硫脲衍生物的抗微生物剂和抗溃疡剂